First Tracks Biotherapeutics, Inc. TRAX
Set alert
At close · Oct 30
After hours · Oct 30, 4:43 PM ET
- YTD
- +137.26%
- 1 year
- +137.26%
- Open
- 45.03
- Prev close
- 45.23
- Mkt cap
- 1.89B
- Vol
- 434.20K
- Avg vol
- 833.99K
- EPS
- -4.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 43.36
- High
- 45.87
- Forward P/E
- -12.45
- Beta
- 0.00
- Short ratio
- 6.01
- Inst. own
- 88.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 38.86
- 200-d avg
- 30.42
- 1y target
- 74.17
5D chart
Signals (111)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| RSI: Oversold | Oct 29, 3:25 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:40 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 3 days ago |
| RSI: Overbought | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 4 days ago |
| RSI: Overbought | Oct 27, 11:40 AM | 4 days ago |
| RSI: Overbought | Oct 27, 11:15 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:50 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 5 days ago |
News
-
2 weeks ago benzinga.com
Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90
Leerink Partners analyst David Risinger maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $70 to $90.
-
2 weeks ago benzinga.com
First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Investors
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory…
2 weeks ago globenewswire.com
First Tracks Biotherapeutics Announces $200 Million Private Placement
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
2 weeks ago seekingalpha.com
First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
First Tracks Biotherapeutics offers a differentiated CD122 antagonist, ANB033, showing promising Phase 1b data in celiac disease with statistically significant histology and symptom improvements.…
-
2 weeks ago benzinga.com
Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60
Canaccord Genuity analyst Edward Nash maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $50 to $60.
-
2 weeks ago benzinga.com
Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70
Evercore ISI Group analyst Gavin Clark-Gartner maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $65 to $70.
-
2 weeks ago benzinga.com
Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $70
Wells Fargo analyst Derek Archila maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $62 to $70.
2 weeks ago defenseworld.net
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
First Tracks Biotherapeutics (NASDAQ: TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met…
2 weeks ago marketbeat.com
First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals
First Tracks Biotherapeutics NASDAQ: TRAX reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic…
2 weeks ago benzinga.com
Dow Gains Over 200 Points; Chipotle Shares Move Lower
U.S. stocks traded mixed: Dow rose 0.47%, S&P 500 edged up, Nasdaq fell; energy led gains, while Chipotle dropped after Starbucks denied takeover rumors.
2 weeks ago benzinga.com
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Monday.
2 weeks ago benzinga.com
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed; First Tracks Biotherapeutics surged 18% on positive celiac trial results, while C3.ai, Liquidia and others also gained.
2 weeks ago benzinga.com
Stock Market Today: S&P 500, Dow Futures Gain, Nasdaq 100 Falls as Iran Flags ‘Inadequate’ US Response to Peace Terms — SMP, QMCO, SVRN in Focus (UPDATED)
U.S. stock futures were mixed on Monday, as the Dow Jones and S&P 500 indices rose, while the Nasdaq 100 index fell.
2 weeks ago benzinga.com
Why Is First Tracks Biotherapeutics Stock Soaring Monday?
First Tracks Biotherapeutics (TRAX) stock surged 13% on positive Phase 1b celiac disease trial results for ANB033. Read the update.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million. DataMEDS AI…
-
2 weeks ago benzinga.com
First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptomsLS mean change from baseline in Vh:Cd ratio of -0.17 on…
2 weeks ago benzinga.com
Why J-Star Holding Shares Are Trading Higher By Around 128%; Here Are 20 Stocks Moving Premarket
J-Star Holding surged 127.9% premarket after funding U.S. drone-frame expansion; Linkers and VCI gained, while Vivakor and China SXT fell.
2 weeks ago globenewswire.com
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
-
1 month ago benzinga.com
Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50
Canaccord Genuity analyst Edward Nash initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $50.
1 month ago benzinga.com
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.
-
1 month ago benzinga.com
Evercore ISI Group Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $65
Evercore ISI Group initiates coverage on First Tracks (NASDAQ:TRAX) with a Outperform rating and announces Price Target of $65.
-
1 month ago benzinga.com
Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100
Guggenheim analyst Yatin Suneja initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $100.
1 month ago defenseworld.net
Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) Director J. Anthony Ware sold 39,265 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $57 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates First Tracks (NASDAQ:TRAX) with a Buy and maintains $57 price target.
1 month ago benzinga.com
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
2 months ago globenewswire.com
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
-
2 months ago benzinga.com
Barclays Maintains Overweight on First Tracks, Raises Price Target to $65
Barclays analyst Etzer Darout maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $48 to $65.
2 months ago benzinga.com
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
First Tracks Biotherapeutics Inc (NASDAQ:TRAX) reported a narrower loss for the second quarter on Wednesday.
2 months ago benzinga.com
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on First Tracks, Raises Price Target to $70
Wedbush analyst Martin Fan maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $60 to $70.
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on First Tracks, Raises Price Target to $95
Piper Sandler analyst Yasmeen Rahimi maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $54 to $95.
2 months ago benzinga.com
Brinker International To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts changed outlook on top names. Truist, Morgan Stanley, B of A Securities, HC Wainwright, Baird, and Stephens & Co. altered price targets for various stocks.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $57
HC Wainwright & Co. analyst Emily Bodnar maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $44 to $57.
-
2 months ago benzinga.com
First Tracks Q2 EPS $(0.95) Up From $(1.47) YoY
First Tracks (NASDAQ:TRAX) reported quarterly losses of $(0.95) per share. This is a 35.37 percent increase over losses of $(1.47) per share from the same period last year.
2 months ago globenewswire.com
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways…
-
2 months ago benzinga.com
UBS Maintains Buy on First Tracks, Raises Price Target to $65
UBS analyst Michael Yee maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $45 to $65.
-
3 months ago benzinga.com
Wedbush Maintains Outperform on First Tracks, Raises Price Target to $60
Wedbush analyst Martin Fan maintains First Tracks (NASDAQ:TRAX) with a Outperform and raises the price target from $30 to $60.
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $55
Wells Fargo analyst Derek Archila maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $30 to $55.
3 months ago benzinga.com
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and technology order. Other big gainers include NIPG, FBRX, TRAX, GENI, BMNR, OMER, ASAN, EIKN, IONQ, and…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX)…
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Niki BioSolutions (NASDAQ:NIKI) stock moved upwards by 44.7% to $13.01 during Thursday's pre-market session. The company's market cap stands at $73.2 million. Zhengye Biotechnology…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals…
3 months ago benzinga.com
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guidance. Other gainers: UTZ, AEHR, PKE, FWRD, HELP, SECZ, DOCN, TRAX, PVLA, COIN.
-
3 months ago benzinga.com
Barclays Maintains Overweight on First Tracks, Raises Price Target to $48
Barclays analyst Etzer Darout maintains First Tracks (NASDAQ:TRAX) with a Overweight and raises the price target from $40 to $48.
3 months ago defenseworld.net
First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of First Tracks Biotherapeutics (NASDAQ: TRAX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the stock,…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $44
HC Wainwright & Co. analyst Emily Bodnar maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $30 to $44.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences…
3 months ago benzinga.com
Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On Thursday
U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers include FBRX, BBIO, TRAX, LASR, ONTO, ALNY, ICHR, LITE, ARM, LRCX, KLAC, and FORM.
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $30 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates First Tracks (NASDAQ:TRAX) with a Buy and maintains $30 price target.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session